| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.6 | -3.1 |
| Net income | -2.6 | -3.1 |
| EPS (diluted, $ a share) | $-0.58 | $-1.96 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: OGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Oragenics Inc: key numbers
- Share price
- $0.1980Close, Nov 16
- Market cap
- $893K
- Shares outstanding
- 4.51MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oragenics Inc
All →Oragenics Investor Presentation
Oragenics, Inc. announced that its Chief Medical Officer, James P. Kelly, will deliver a presentation at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The presentation, titled 'Successful Case Studies', will be used during the forum and has been filed as a formal exhibit to the company's 8-K.
- Counterparty
- IPAC-RS 2026 Nasal Innovation Forum